Redefining WeightWatchers' role in a world where medication changes the way consumers eat, shop, and manage their health.
With only 20 minutes and no pre-read, the presentation had to be brief, visual, and hard-hitting. The ask was not to present a finished product. It was to earn approval to explore a future offering that could support consumers during and after GLP-1 use.
The narrative moves from threat, to proof, to right to win. Each section answers the CEO's likely objection before moving to the next implication.
GLP-1s do not eliminate the weight-management job. They change which part of the job consumers still need help with.
Show household-scale adoption and the downstream changes in food, restaurants, nutrition, and identity.
Appetite suppression is not the same as learning how to nourish yourself, sustain strength, or maintain progress.
Recommend a product-led exploration rooted in WeightWatchers' strengths: nutrition, behavior change, and long-term maintenance.
U.S. households already includes a current GLP-1 user. That could become 2 in 5 as barriers like cost, coverage, access, and format fall.
GLP-1s suppress appetite and reduce food noise, removing one of the hardest parts of the traditional weight-management job. The implication for WeightWatchers is not to abandon its core — it is to evolve around the needs medication does not solve.
The evidence ladder combines adoption, attention, category response, and lived behavior. Together, the signals show why WeightWatchers should act before adoption is fully mature.
Current use or consideration if cost, coverage, access, and format barriers improve.
In multi-person households with a GLP-1 user versus comparable non-user households.
Users report a meaningful shift in their relationship with food — not just a lower number on the scale.
Spending rises around six months after treatment begins, signaling a shift in confidence and identity.
Early moves from food and restaurant brands make the shift legible: the opportunity is not only medical access. It is what people need to eat, feel, and do differently.
Chipotle introduced a High Protein Menu, including two items specifically called out as GLP-1-friendly — a signal that portion and nutrient needs are changing the menu conversation.
Category response →Vital Pursuit is a line of portion-aligned, nutrient-dense meals designed to support GLP-1 users with essential nutrients.
Product response →During treatment, consumers still need enough protein, nutrients, hydration, energy, and strength. And when treatment changes or ends, they need routines that can carry progress forward.
GLP-1s can change appetite. They do not automatically teach consumers how to nourish themselves well, maintain strength, or build routines for what comes after treatment.
Translate smaller portions into enough protein, nutrients, hydration, energy, and strength — without reducing the job to calorie count.
Build guidance, tools, and routines around changing cravings, dining habits, food discovery, and the realities of everyday life.
Support consumers as treatment changes or ends, when cost and other barriers can interrupt progress and old behaviors may return.
The recommendation is product-led: explore how WeightWatchers can support nutrition and behavior during treatment, then help consumers maintain progress through treatment changes or discontinuation.
The recommendation acknowledges WeightWatchers' previous attempts, then draws a sharper line around what should be different this time.
The wellness rebrand was largely a brand move. The initial GLP-1 pivot expanded medication access without fully activating WeightWatchers' differentiated strengths.
Start learning before the market is fully mature. Build around what WeightWatchers can credibly own as consumer needs evolve.
Research was synthesized into a concise five-page executive narrative for a quantitative, visually oriented CEO audience.